An open-label phase 2a study investigating the efficacy and safety of a cathepsin S inhibitor in patients with moderate-to-severe psoriasis

J Am Acad Dermatol. 2022 Nov;87(5):1089-1091. doi: 10.1016/j.jaad.2021.09.074. Epub 2021 Dec 11.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cathepsins* / adverse effects
  • Cathepsins* / antagonists & inhibitors
  • Humans
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • cathepsin S
  • Cathepsins